We serve 4-(2-Methoxyethyl)phenol CAS:56718-71-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Contact us for information like 4-(2-Methoxyethyl)phenol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-[4-(2-methoxyethyl)phenoxy]propylene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-[4-(2-methoxyethyl)phenoxy]propylene Use and application,4-methoxyethylphenol technical grade,usp/ep/jp grade.
Related News: Most foreign drugmakers offered Beijing the lowest prices globally in a recent round of negotiations in order to get some of their new products included in national insurance program, a move that will help them gain access to more patients in less-affluent cities, officials said on Thursday.1-Ethoxycarbonyl-5-methyl-(3R)-3-tert-butyl-dimethylsilyloxypentanedioate manufacturer Most foreign drugmakers offered Beijing the lowest prices globally in a recent round of negotiations in order to get some of their new products included in national insurance program, a move that will help them gain access to more patients in less-affluent cities, officials said on Thursday.3-(2-amino-2-oxoethyl)-5-methylhexanoic acid supplier Beneficial drug raw materials refer to the active pharmaceutical ingredients used in the manufacture of original research drugs (patent drugs). They are mainly used to meet the needs of original multinational pharmaceutical companies and emerging biopharmaceutical companies for innovative drugs in clinical drug research, registration approval and commercialization sales , Which also contains advanced intermediates used in the manufacture of the drug substance that need to be regulated by regulatory authorities.3-Fluoro-5-methylbenzoic acid vendor Under the terms of this agreement, Inceptua will support Onconova through the pre-approval provision of intravenous rigosertib initially into a number of countries including: Australia, Denmark, Finland, France, Ireland, Italy, the Netherlands, Portugal, South Africa, Spain, and the UK.Under the terms of this agreement, Inceptua will support Onconova through the pre-approval provision of intravenous rigosertib initially into a number of countries including: Australia, Denmark, Finland, France, Ireland, Italy, the Netherlands, Portugal, South Africa, Spain, and the UK.
